Comparison
Bromantane vs PT-141
Side-by-side of Bromantane and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | Bromantane | PT-141 |
|---|---|---|
| Category | nootropic | peptide |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 11 | 2.7 |
| Typical dose (mg) ↗ | 75 | 1.75 |
| Dosing frequency | daily, morning | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral | subcutaneous |
| Onset (hr) | 3 | 0.75 |
| Peak (hr) | 168 | 1.5 |
| Molecular weight | 280.21 | 1025.18 |
| Molecular formula | C16H20BrN | C50H68N14O10 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled in the US | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Not recommended | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | 87913-26-6 | 189691-06-3 |
| PubChem CID | 9576456 | 9941379 |
| Wikidata | Q4093816 | Q422059 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you cannot self-administer injections, Bromantane is the only oral option in this pair.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and PT-141?
Bromantane and PT-141 differ in category (nootropic vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or PT-141?
Bromantane half-life is 11 hours; PT-141 half-life is 2.7 hours.
Can you stack Bromantane with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper